{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:35Z","timestamp":1790313515068,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":91,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Hypoparathyroidism (HP) is a condition of parathyroid hormone (PTH) deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of therapy consists of vitamin D and calcium supplements, as well as adjunct Natpara (PTH(1-84)). However, neither therapy optimally controls urinary calcium (uCa) or significantly reduces the incidence of hypercalcemia and hypocalcemia. TransCon PTH, a sustained-release prodrug of PTH(1-34) in development for the treatment of HP, was designed to overcome these limitations. To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys. TransCon PTH demonstrated a half-life of 28 and 34 hours in rats and monkeys, respectively. After repeated dosing, an infusion-like profile of the released PTH, characterized by low peak-to-trough levels, was obtained in both species. In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP). In monkeys, at a single dose of TransCon PTH that increased sCa levels within the normal range, a concurrent decrease in uCa excretion was observed. In 4-week repeat-dose studies in intact rats and monkeys, uCa excretion was comparable to controls across all dose levels despite increases in sCa levels. Further, in a rat model of HP, TransCon PTH normalized sCa and sP levels 24\u2009hours per day. This was in contrast to only transient trends toward normalization of sCa and sP levels with an up to 6-fold higher molar dose of PTH(1-84). After repeated dosing to HP rats, uCa excretion transiently increased, corresponding to increases in sCa above normal range, but at the end of the treatment period, uCa excretion was generally comparable to sham controls. TransCon PTH was well tolerated and the observed pharmacokinetics and pharmacodynamics were in line with the expected action of physiological replacement of PTH. \u00a9 2019 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.3824","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T12:58:06Z","timestamp":1562763486000},"page":"2075-2086","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-6146","authenticated-orcid":false,"given":"Lars","family":"Holten-Andersen","sequence":"first","affiliation":[{"name":"Ascendis Pharma A\/S, Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Pihl","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Zettler","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Maitro","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Baron","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Heinig","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wegge","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Krusch","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Faltinger","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Killian","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennett","family":"Sprogoe","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B","family":"Karpf","sequence":"additional","affiliation":[{"name":"Ascendis Pharma Inc Palo Alto CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke Miller","family":"Breinholt","sequence":"additional","affiliation":[{"name":"Ascendis Pharma A\/S, Hellerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Cleemann","sequence":"additional","affiliation":[{"name":"Ascendis Pharma GmbH Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"issue":"10","key":"2024021014453898000_jbmr3824-bib-0001","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2024021014453898000_jbmr3824-bib-0002","first-page":"172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2024021014453898000_jbmr3824-bib-0003","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice","volume":"359","author":"Shoback","year":"2008","journal-title":"Hypoparathyroidism. N Engl J Med"},{"issue":"2","key":"2024021014453898000_jbmr3824-bib-0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1590\/S0004-27302010000200019","article-title":"Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement","volume":"54","author":"Rubin","year":"2010","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2024021014453898000_jbmr3824-bib-0005","author":"BLA #125511, Natpara","year":"2015"},{"key":"2024021014453898000_jbmr3824-bib-0006"},{"issue":"6","key":"2024021014453898000_jbmr3824-bib-0007","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/ki.2014.316","article-title":"Molecular interactions of FGF23 and PTH in phosphate regulation","volume":"86","author":"Lanske","year":"2014","journal-title":"Kidney Int."},{"issue":"3","key":"2024021014453898000_jbmr3824-bib-0008","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr."},{"issue":"2","key":"2024021014453898000_jbmr3824-bib-0009","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021014453898000_jbmr3824-bib-0010","volume-title":"PEGylated protein drugs: basic science and clinical applications. Milestones in drug therapy","author":"Webster","year":"2009"},{"issue":"3","key":"2024021014453898000_jbmr3824-bib-0011","doi-asserted-by":"crossref","DOI":"10.3390\/ph11030075","article-title":"Polyethylene glycol exposure with antihemophilic factor (recombinant), PEGylated (rurioctocog alfa pegol) and other therapies indicated for the pediatric population: history and safety","volume":"11","author":"Stidl","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024021014453898000_jbmr3824-bib-0012","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jpba.2014.06.004","article-title":"Development and validation of a novel cell-based assay for potency determination of human parathyroid hormone (PTH)","volume":"98","author":"Hohenstein","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2024021014453898000_jbmr3824-bib-0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5582\/ddt.2015.01002","article-title":"Circadian rhythm of serum 25 (OH) vitamin D, calcium and phosphorus levels in the treatment and management of type-2 diabetic patients","volume":"9","author":"Masood","year":"2015","journal-title":"Drug Discov Ther"},{"issue":"7","key":"2024021014453898000_jbmr3824-bib-0014","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/jbmr.2812","article-title":"Concurrent hypoparathyroidism is associated with impaired physical function and quality of life in hypothyroidism","volume":"31","author":"Sikjaer","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014453898000_jbmr3824-bib-0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA."},{"issue":"10","key":"2024021014453898000_jbmr3824-bib-0016","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024021014453898000_jbmr3824-bib-0017","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024021014453898000_jbmr3824-bib-0018","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"2024021014453898000_jbmr3824-bib-0019","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1038\/ncomms13384","article-title":"Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism","volume":"7","author":"Tamura","year":"2016","journal-title":"Nat Commun."},{"issue":"2","key":"2024021014453898000_jbmr3824-bib-0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bph.14028","article-title":"Repurposing a novel parathyroid hormone (PTH) analog to treat hypoparathyroidism","volume":"175","author":"Krishnan","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2024021014453898000_jbmr3824-bib-0021","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/jbmr.2917","article-title":"Prolonged pharmacokinetic and pharmacodynamic actions of a pegylated parathyroid hormone (1-34) peptide fragment","volume":"32","author":"Guo","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024021014453898000_jbmr3824-bib-0022","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1\u201334]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"2024021014453898000_jbmr3824-bib-0023","author":"NDA # 21-318 Forteo [teriparatide]","year":"2002"},{"key":"2024021014453898000_jbmr3824-bib-0024","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/bs.ircmb.2016.05.004","article-title":"The calcium-sensing receptor in health and disease","volume":"327","author":"Diaz-Soto","year":"2016","journal-title":"Int Rev Cell Mol Biol"},{"issue":"4","key":"2024021014453898000_jbmr3824-bib-0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ecl.2018.07.008","article-title":"Skeletal manifestations of hypoparathyroidism","volume":"47","author":"Rubin","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"2","key":"2024021014453898000_jbmr3824-bib-0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00198-016-3750-0","article-title":"Bone imaging in hypoparathyroidism","volume":"28","author":"Silva","year":"2017","journal-title":"Osteoporos Int."},{"issue":"1","key":"2024021014453898000_jbmr3824-bib-0027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024021014453898000_jbmr3824-bib-0028","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2024021014453898000_jbmr3824-bib-0029","author":"FDA","year":"2014"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.3824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.3824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/11\/2075\/56653921\/jbmr3824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/34\/11\/2075\/56653921\/jbmr3824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:04:34Z","timestamp":1710327874000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/34\/11\/2075-2086\/7605779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,7,10]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3824","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736177715.793576365","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"2018-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}